Review



active human hpse1  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bio-Techne corporation active human hpse1
    Relation between <t>HPSE1</t> and HPSE2 regulation in glomerular disease reveals a possible connection (A) . Renal cortical HPSE2 mRNA expression of HPSE1 KO mice treated with or without LPS for 2 days (B) . Renal cortical HPSE2 protein expression of HPSE1 KO mice treated with or without STZ for 16 weeks (C) . Renal cortical HPSE2 mRNA expression of type 2 diabetic mice treated with HPSE1 inhibitor SST0001 or left untreated (D) . Relative HPSE1 activity of untreated wild-type mice or HPSE2 KO mice (E) . Glomerular HS expression of untreated wild-type mice or HPSE2 KO mice. Data are expressed as mean ± SEM. n ≥ 3 * p < 0.05. HPSE2, heparanase-2; AU, arbitrary units; HPSE1, heparanase-1; KO, knock-out; STZ, streptozotocin.
    Active Human Hpse1, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/active human hpse1/product/Bio-Techne corporation
    Average 94 stars, based on 27 article reviews
    active human hpse1 - by Bioz Stars, 2026-06
    94/100 stars

    Images

    1) Product Images from "Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy"

    Article Title: Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2023.1098184

    Relation between HPSE1 and HPSE2 regulation in glomerular disease reveals a possible connection (A) . Renal cortical HPSE2 mRNA expression of HPSE1 KO mice treated with or without LPS for 2 days (B) . Renal cortical HPSE2 protein expression of HPSE1 KO mice treated with or without STZ for 16 weeks (C) . Renal cortical HPSE2 mRNA expression of type 2 diabetic mice treated with HPSE1 inhibitor SST0001 or left untreated (D) . Relative HPSE1 activity of untreated wild-type mice or HPSE2 KO mice (E) . Glomerular HS expression of untreated wild-type mice or HPSE2 KO mice. Data are expressed as mean ± SEM. n ≥ 3 * p < 0.05. HPSE2, heparanase-2; AU, arbitrary units; HPSE1, heparanase-1; KO, knock-out; STZ, streptozotocin.
    Figure Legend Snippet: Relation between HPSE1 and HPSE2 regulation in glomerular disease reveals a possible connection (A) . Renal cortical HPSE2 mRNA expression of HPSE1 KO mice treated with or without LPS for 2 days (B) . Renal cortical HPSE2 protein expression of HPSE1 KO mice treated with or without STZ for 16 weeks (C) . Renal cortical HPSE2 mRNA expression of type 2 diabetic mice treated with HPSE1 inhibitor SST0001 or left untreated (D) . Relative HPSE1 activity of untreated wild-type mice or HPSE2 KO mice (E) . Glomerular HS expression of untreated wild-type mice or HPSE2 KO mice. Data are expressed as mean ± SEM. n ≥ 3 * p < 0.05. HPSE2, heparanase-2; AU, arbitrary units; HPSE1, heparanase-1; KO, knock-out; STZ, streptozotocin.

    Techniques Used: Expressing, Activity Assay, Knock-Out

    Inhibition of HPSE1 activity is dose-dependently achieved by HPSE2 protein and HPSE2 peptides. Dose response inhibition of recombinant human HPSE1 with the full HPSE2 protein (A) and HPSE2 peptides (B,C) . HPSE2, heparanase-2; HPSE1, heparanase-1.
    Figure Legend Snippet: Inhibition of HPSE1 activity is dose-dependently achieved by HPSE2 protein and HPSE2 peptides. Dose response inhibition of recombinant human HPSE1 with the full HPSE2 protein (A) and HPSE2 peptides (B,C) . HPSE2, heparanase-2; HPSE1, heparanase-1.

    Techniques Used: Inhibition, Activity Assay, Recombinant

    HPSE2 protein and peptides treatment have beneficial effects in LPS-induced glomerulonephritis (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix of 381–410, 391–420, and 401–430. Data are expressed as mean ± SEM. n ≥ 4 * p < 0.05, ** p < 0.01, *** p < 0.001. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, HPSE2 peptide mix of 381–410, 391–420, and 401–430; BUN, Blood urea nitrogen plasma level.
    Figure Legend Snippet: HPSE2 protein and peptides treatment have beneficial effects in LPS-induced glomerulonephritis (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix of 381–410, 391–420, and 401–430. Data are expressed as mean ± SEM. n ≥ 4 * p < 0.05, ** p < 0.01, *** p < 0.001. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, HPSE2 peptide mix of 381–410, 391–420, and 401–430; BUN, Blood urea nitrogen plasma level.

    Techniques Used: Injection, Expressing

    HPSE2 protein and peptides treatment beneficially affect experimental STZ-induced diabetic nephropathy (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix. Data are expressed as mean ± SEM. n ≥ 5 * p < 0.05. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, peptide mix; BUN, Blood urea nitrogen plasma level; STZ, streptozotocin.
    Figure Legend Snippet: HPSE2 protein and peptides treatment beneficially affect experimental STZ-induced diabetic nephropathy (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix. Data are expressed as mean ± SEM. n ≥ 5 * p < 0.05. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, peptide mix; BUN, Blood urea nitrogen plasma level; STZ, streptozotocin.

    Techniques Used: Injection, Expressing



    Similar Products

    active human hpse1  (Bio-Techne corporation)
    94
    Bio-Techne corporation active human hpse1
    Relation between <t>HPSE1</t> and HPSE2 regulation in glomerular disease reveals a possible connection (A) . Renal cortical HPSE2 mRNA expression of HPSE1 KO mice treated with or without LPS for 2 days (B) . Renal cortical HPSE2 protein expression of HPSE1 KO mice treated with or without STZ for 16 weeks (C) . Renal cortical HPSE2 mRNA expression of type 2 diabetic mice treated with HPSE1 inhibitor SST0001 or left untreated (D) . Relative HPSE1 activity of untreated wild-type mice or HPSE2 KO mice (E) . Glomerular HS expression of untreated wild-type mice or HPSE2 KO mice. Data are expressed as mean ± SEM. n ≥ 3 * p < 0.05. HPSE2, heparanase-2; AU, arbitrary units; HPSE1, heparanase-1; KO, knock-out; STZ, streptozotocin.
    Active Human Hpse1, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/active human hpse1/product/Bio-Techne corporation
    Average 94 stars, based on 1 article reviews
    active human hpse1 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Relation between HPSE1 and HPSE2 regulation in glomerular disease reveals a possible connection (A) . Renal cortical HPSE2 mRNA expression of HPSE1 KO mice treated with or without LPS for 2 days (B) . Renal cortical HPSE2 protein expression of HPSE1 KO mice treated with or without STZ for 16 weeks (C) . Renal cortical HPSE2 mRNA expression of type 2 diabetic mice treated with HPSE1 inhibitor SST0001 or left untreated (D) . Relative HPSE1 activity of untreated wild-type mice or HPSE2 KO mice (E) . Glomerular HS expression of untreated wild-type mice or HPSE2 KO mice. Data are expressed as mean ± SEM. n ≥ 3 * p < 0.05. HPSE2, heparanase-2; AU, arbitrary units; HPSE1, heparanase-1; KO, knock-out; STZ, streptozotocin.

    Journal: Frontiers in Pharmacology

    Article Title: Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy

    doi: 10.3389/fphar.2023.1098184

    Figure Lengend Snippet: Relation between HPSE1 and HPSE2 regulation in glomerular disease reveals a possible connection (A) . Renal cortical HPSE2 mRNA expression of HPSE1 KO mice treated with or without LPS for 2 days (B) . Renal cortical HPSE2 protein expression of HPSE1 KO mice treated with or without STZ for 16 weeks (C) . Renal cortical HPSE2 mRNA expression of type 2 diabetic mice treated with HPSE1 inhibitor SST0001 or left untreated (D) . Relative HPSE1 activity of untreated wild-type mice or HPSE2 KO mice (E) . Glomerular HS expression of untreated wild-type mice or HPSE2 KO mice. Data are expressed as mean ± SEM. n ≥ 3 * p < 0.05. HPSE2, heparanase-2; AU, arbitrary units; HPSE1, heparanase-1; KO, knock-out; STZ, streptozotocin.

    Article Snippet: The inhibition of HPSE1 activity by HPSE2 protein and peptides was determined by the commercially available HPSE1 assay kit and an in-house developed HPSE1 activity assay, which was optimized by the use of recombinant active human HPSE1 (Bio-techne, Abingdon, United Kingdom, Cat#7570-GH-005).

    Techniques: Expressing, Activity Assay, Knock-Out

    Inhibition of HPSE1 activity is dose-dependently achieved by HPSE2 protein and HPSE2 peptides. Dose response inhibition of recombinant human HPSE1 with the full HPSE2 protein (A) and HPSE2 peptides (B,C) . HPSE2, heparanase-2; HPSE1, heparanase-1.

    Journal: Frontiers in Pharmacology

    Article Title: Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy

    doi: 10.3389/fphar.2023.1098184

    Figure Lengend Snippet: Inhibition of HPSE1 activity is dose-dependently achieved by HPSE2 protein and HPSE2 peptides. Dose response inhibition of recombinant human HPSE1 with the full HPSE2 protein (A) and HPSE2 peptides (B,C) . HPSE2, heparanase-2; HPSE1, heparanase-1.

    Article Snippet: The inhibition of HPSE1 activity by HPSE2 protein and peptides was determined by the commercially available HPSE1 assay kit and an in-house developed HPSE1 activity assay, which was optimized by the use of recombinant active human HPSE1 (Bio-techne, Abingdon, United Kingdom, Cat#7570-GH-005).

    Techniques: Inhibition, Activity Assay, Recombinant

    HPSE2 protein and peptides treatment have beneficial effects in LPS-induced glomerulonephritis (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix of 381–410, 391–420, and 401–430. Data are expressed as mean ± SEM. n ≥ 4 * p < 0.05, ** p < 0.01, *** p < 0.001. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, HPSE2 peptide mix of 381–410, 391–420, and 401–430; BUN, Blood urea nitrogen plasma level.

    Journal: Frontiers in Pharmacology

    Article Title: Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy

    doi: 10.3389/fphar.2023.1098184

    Figure Lengend Snippet: HPSE2 protein and peptides treatment have beneficial effects in LPS-induced glomerulonephritis (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with LPS (2 days) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix of 381–410, 391–420, and 401–430. Data are expressed as mean ± SEM. n ≥ 4 * p < 0.05, ** p < 0.01, *** p < 0.001. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, HPSE2 peptide mix of 381–410, 391–420, and 401–430; BUN, Blood urea nitrogen plasma level.

    Article Snippet: The inhibition of HPSE1 activity by HPSE2 protein and peptides was determined by the commercially available HPSE1 assay kit and an in-house developed HPSE1 activity assay, which was optimized by the use of recombinant active human HPSE1 (Bio-techne, Abingdon, United Kingdom, Cat#7570-GH-005).

    Techniques: Injection, Expressing

    HPSE2 protein and peptides treatment beneficially affect experimental STZ-induced diabetic nephropathy (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix. Data are expressed as mean ± SEM. n ≥ 5 * p < 0.05. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, peptide mix; BUN, Blood urea nitrogen plasma level; STZ, streptozotocin.

    Journal: Frontiers in Pharmacology

    Article Title: Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy

    doi: 10.3389/fphar.2023.1098184

    Figure Lengend Snippet: HPSE2 protein and peptides treatment beneficially affect experimental STZ-induced diabetic nephropathy (A) . BUN, (B) . plasma creatinine, and (C) . Urinary albumin/creatinine ratio of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix (D) . Cortical HPSE1, (E) . cortical TNF-α, (F) . cortical IL-6 mRNA expression of mice injected with STZ (12 weeks) and treated with different concentrations of HPSE2 protein or HPSE2 peptide mix. Data are expressed as mean ± SEM. n ≥ 5 * p < 0.05. HPSE2, heparanase-2; HPSE1, heparanase-1; Prt, His-mHPSE2 protein; pep, peptide mix; BUN, Blood urea nitrogen plasma level; STZ, streptozotocin.

    Article Snippet: The inhibition of HPSE1 activity by HPSE2 protein and peptides was determined by the commercially available HPSE1 assay kit and an in-house developed HPSE1 activity assay, which was optimized by the use of recombinant active human HPSE1 (Bio-techne, Abingdon, United Kingdom, Cat#7570-GH-005).

    Techniques: Injection, Expressing